NAMI-A, i. e. (imH)[trans-RuCl 4 (dmso-S)(im)] (im = imidazole, dmso = dimethylsulfoxide), is a Ru(III) complex that, after extensive preclinical investigations that evidenced its remarkable and specific activity against metastases, has recently and successfully completed a Phase I trial (first ruthenium complex ever to reach clinical testing). This review article, after a brief summary of the main chemical and pharmacological aspects of NAMI-A, focuses on the development of new classes of ruthenium complexes originated from the NAMI-A frame.
Ruthenium antimetastatic agents / Alessio, E., Mestroni, G., Bergamo, A., Sava, G.. - In: CURRENT TOPICS IN MEDICINAL CHEMISTRY. - ISSN 1568-0266. - STAMPA. - 4:(2004), pp. 1525-1535. [10.2174/1568026043387421]
Ruthenium antimetastatic agents
ALESSIO, ENZO;BERGAMO A.;SAVA, GIANNI
2004-01-01
Abstract
NAMI-A, i. e. (imH)[trans-RuCl 4 (dmso-S)(im)] (im = imidazole, dmso = dimethylsulfoxide), is a Ru(III) complex that, after extensive preclinical investigations that evidenced its remarkable and specific activity against metastases, has recently and successfully completed a Phase I trial (first ruthenium complex ever to reach clinical testing). This review article, after a brief summary of the main chemical and pharmacological aspects of NAMI-A, focuses on the development of new classes of ruthenium complexes originated from the NAMI-A frame.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
